Development-stage medical device company Cerebain Biotech said today that it’s planning to begin development of a medical device designed to treat Alzheimer’s disease and dementia.
The minimally invasive implantable device is designed for omentum stimulation, which the company said has a “clinically observable, positive impact” on cognitive function related to dementia and Alzheimer’s disease.
The device can be adjusted non-invasively to account for a “range of factors” including frequency, strength of stimulation and location, according to the company’s website.
“We would like to offer a heartfelt thank you to each and every shareholder: past, current, and future for your unwavering support of our company and for also taking the time to read this important shareholder update. We are extremely excited to continue to move forward with our development plan and to do everything in our power to eradicate Alzheimer’s disease while adding to shareholder value,” president Eric Clemons said in prepared remarks.
Cerebain also said it recently relocated its headquarters from Dallas to Costa Mesa, Calif., as it seeks FDA approval for the device. The company said it plans to allocate resources for pursuing FDA approval over the coming months.
The company said it also inked a memorandum of understanding with the department of neurodegenerative diseases at Poland’s Mossakowski Medical Research Centre for testing the device once development is completed.
